Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 12Urinary Bladder Neoplasms 8Prostatic Neoplasms 8Neoplasm Metastasis 4Lung Neoplasms 4Carcinoma, Transitional Cell 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Melanoma 3Carcinoma, Non-Small-Cell Lung 3Uterine Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Ovarian Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urologic Neoplasms 1Thrombocytosis 1

Interventions

Erlotinib Hydrochloride 2Bevacizumab 2spartalizumab 1pamiparib 1atezolizumab 1Temozolomide 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Everolimus 1Disulfides 1Contrast Media 1Botulinum Toxins, Type A 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary leiomyomatosis and renal cell cancer × Immunoglobulin G × Genitourinary × Clear all
NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡